Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Leukemia relapse study halted: could a blood test have predicted it?

NCT ID NCT05224661

Knowledge-focused Sponsor: Center for International Blood and Marrow Transplant Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if a sensitive molecular test could predict relapse in adults with acute myeloid leukemia (AML) who had a stem cell transplant. Researchers planned to follow 303 patients in remission, comparing outcomes between those with and without detectable disease markers. The study was terminated early, so its full potential remains unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

303 people

The number who actually took part.

Started

Aug 2022

Finished

Dec 2025

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with AML in complete remission undergoing alloHCT

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Aged at least 18 years old at time of consent 4. Diagnosed with AML, in complete remission 1. Complete remission (CR) definition per local institutional criteria 2. CR with incomplete hematologic recovery (CRi) is not an exclusion criterion 3. MRD positivity is not an exclusion criterion 5. Undergoing alloHCT 6. Has a diagnostic AML specimen available Exclusion Criteria: 1. Diagnosis of acute promyelocytic leukemia 2. Prior alloHCT

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia in remission are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukemia in remission

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

  • H. Lee Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Levine Cancer Institute

    Charlotte, North Carolina, 28204, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10021, United States

  • New York Presbyterian / Weill Cornell Medical Center

    New York, New York, 10021, United States

  • Northside Hospital

    Atlanta, Georgia, 30342, United States

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, 14263, United States

  • Stanford University

    Stanford, California, 94305, United States

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • University of California, San Francisco

    San Francisco, California, 94143, United States

  • University of Chicago Medicine

    Chicago, Illinois, 60637, United States

  • University of Colorado

    Aurora, Colorado, 80045, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.